Patents by Inventor Ania GONZÁLEZ CORTEZÓN

Ania GONZÁLEZ CORTEZÓN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fixed dose composition of paracetamol: amitriptyline and method for the treatment of mixed cancer pain
    Patent number: 11590091
    Abstract: The present invention describes a pharmaceutical composition at a fixed dose of paracetamol and specifically amitriptyline supported by the pharmacological interaction and safety studies that show its synergy for the anti-allodynic, the mechanical anti-hypernociceptive effects and for the reduction of persistent pain, proportions, safety and neuroprotective capacity. This is aimed to the treatment of mixed pain due to cancer that can be incorporated as another option in the strategy of the WHO analgesic ladder at step 1 for the treatment of mild pain. However, it can also be included in higher steps associated with opioids for the treatment of pain of greater intensity and potentially decrease the escalation of its doses and adverse effects such as tolerance and hyperalgesia.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: February 28, 2023
    Assignee: CENTRO DE INVESTIGACIÓN Y DESARROLLO DE MEDICAMENT
    Inventors: Bárbara Beatriz Garrido Suárez, Addis Bellma Menéndez, Ania González Cortezón, Nilia De La Paz Martín-Viaña, Pedro Gilberto Bárzaga Fernández, Rolando Perdomo Morales, Alejandro Saúl Padrón Yaquis
  • FIXED DOSE COMPOSITION OF PARACETAMOL: AMITRIPTYLINE AND METHOD FOR THE TREATMENT OF MIXED CANCER PAIN
    Publication number: 20210236440
    Abstract: The present invention describes a pharmaceutical composition at a fixed dose of paracetamol and specifically amitriptyline supported by the pharmacological interaction and safety studies that show its synergy for the anti-allodynic, the mechanical anti-hypernociceptive effects and for the reduction of persistent pain, proportions, safety and neuroprotective capacity. This is aimed to the treatment of mixed pain due to cancer that can be incorporated as another option in the strategy of the WHO analgesic ladder at step 1 for the treatment of mild pain. However, it can also be included in higher steps associated with opioids for the treatment of pain of greater intensity and potentially decrease the escalation of its doses and adverse effects such as tolerance and hyperalgesia.
    Type: Application
    Filed: May 3, 2019
    Publication date: August 5, 2021
    Inventors: Bárbara Beatriz GARRIDO SUÁREZ, Addis BELLMA MENÉNDEZ, Ania GONZÁLEZ CORTEZÓN, Nilia DE LA PAZ MARTÍN-VIAÑA, Pedro Gilberto BÁRZAGA FERNÁNDEZ, Rolando PERDOMO MORALES, Alejandro Saúl PADRÓN YAQUIS